Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

NCT04397263 is registered in ClinicalTrials.gov with Janssen Pharmaceutical K.K. as lead sponsor.

NCT NCT04397263
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04397263 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
Lead sponsor
Janssen Pharmaceutical K.K.
Phase
Phase 3
Overall status
Completed
Start date
June 10, 2020
Completion date
September 12, 2025
Enrollment
38 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

crohns disease